Endothelial Cell Capture of Heparin-Binding Growth Factors under Flow

Circulation is an important delivery method for both natural and synthetic molecules, but microenvironment interactions, regulated by endothelial cells and critical to the molecule's fate, are difficult to interpret using traditional approaches. In this work, we analyzed and predicted growth factor capture under flow using computer modeling and a three-dimensional experimental approach that includes pertinent circulation characteristics such as pulsatile flow, competing binding interactions, and limited bioavailability. An understanding of the controlling features of this process was desired. The experimental module consisted of a bioreactor with synthetic endothelial-lined hollow fibers under flow. The physical design of the system was incorporated into the model parameters. The heparin-binding growth factor fibroblast growth factor-2 (FGF-2) was used for both the experiments and simulations. Our computational model was composed of three parts: (1) media flow equations, (2) mass transport equations and (3) cell surface reaction equations. The model is based on the flow and reactions within a single hollow fiber and was scaled linearly by the total number of fibers for comparison with experimental results. Our model predicted, and experiments confirmed, that removal of heparan sulfate (HS) from the system would result in a dramatic loss of binding by heparin-binding proteins, but not by proteins that do not bind heparin. The model further predicted a significant loss of bound protein at flow rates only slightly higher than average capillary flow rates, corroborated experimentally, suggesting that the probability of capture in a single pass at high flow rates is extremely low. Several other key parameters were investigated with the coupling between receptors and proteoglycans shown to have a critical impact on successful capture. The combined system offers opportunities to examine circulation capture in a straightforward quantitative manner that should prove advantageous for biologicals or drug delivery investigations.

[1]  K. Schmidt-Nielsen,et al.  Scaling, why is animal size so important? , 1984 .

[2]  Nobuyuki Itoh,et al.  Chondroitin Sulfate/Dermatan Sulfate Hybrid Chains from Embryonic Pig Brain, Which Contain a Higher Proportion of L-Iduronic Acid than Those from Adult Pig Brain, Exhibit Neuritogenic and Growth Factor Binding Activities* , 2004, Journal of Biological Chemistry.

[3]  Winfried Neuhaus,et al.  A novel flow based hollow-fiber blood-brain barrier in vitro model with immortalised cell line PBMEC/C1-2. , 2006, Journal of biotechnology.

[4]  Selim Elhadj,et al.  Chronic pulsatile shear stress impacts synthesis of proteoglycans by endothelial cells: Effect on platelet aggregation and coagulation , 2002, Journal of cellular biochemistry.

[5]  D. Ornitz,et al.  Heparan and chondroitin sulfate on growth plate perlecan mediate binding and delivery of FGF-2 to FGF receptors. , 2007, Matrix biology : journal of the International Society for Matrix Biology.

[6]  M. Nugent,et al.  Potentiation and inhibition of bFGF binding by heparin: a model for regulation of cellular response. , 2000, Biochemistry.

[7]  Jun Zhang,et al.  A Computational Model of FGF-2 Binding and HSPG Regulation Under Flow , 2009, IEEE Transactions on Biomedical Engineering.

[8]  M. Mohammadi,et al.  The FGF family: biology, pathophysiology and therapy , 2009, Nature Reviews Drug Discovery.

[9]  S. Tumova,et al.  Heparan sulfate proteoglycans on the cell surface: versatile coordinators of cellular functions. , 2000, The international journal of biochemistry & cell biology.

[10]  S. Björnsson Quantitation of proteoglycans as glycosaminoglycans in biological fluids using an alcian blue dot blot analysis. , 1998, Analytical biochemistry.

[11]  R. Gallo,et al.  Structural and Sequence Motifs in Dermatan Sulfate for Promoting Fibroblast Growth Factor-2 (FGF-2) and FGF-7 Activity* , 2005, Journal of Biological Chemistry.

[12]  Robert J Linhardt,et al.  Kinetic model for FGF, FGFR, and proteoglycan signal transduction complex assembly. , 2004, Biochemistry.

[13]  C L Cooney,et al.  Heparinase inhibits neovascularization. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[14]  R L Kormos,et al.  Hemodynamics and the vascular endothelial cytoskeleton , 1987, The Journal of cell biology.

[15]  Vanessa Hsei,et al.  Complexation of VEGF with Bevacizumab Decreases VEGF Clearance in Rats , 2002, Pharmaceutical Research.

[16]  F. Hainsworth Scaling: why is animal size so important? , 1985 .

[17]  E. Edelman,et al.  Computational simulations of local vascular heparin deposition and distribution. , 1996, The American journal of physiology.

[18]  E A Gaffney,et al.  A Mass Action Model of a Fibroblast Growth Factor Signaling Pathway and Its Simplification , 2008, Bulletin of mathematical biology.

[19]  E. Edelman,et al.  Kinetics of basic fibroblast growth factor binding to its receptor and heparan sulfate proteoglycan: a mechanism for cooperactivity. , 1992, Biochemistry.

[20]  P. Walicke,et al.  Interactions between basic fibroblast growth factor (FGF) and glycosoaminoglycans in promoting neurite outgrowth , 1988, Experimental Neurology.

[21]  E. Guatteo,et al.  A dynamic model of the blood-brain barrier "in vitro". , 1996, Neurotoxicology.

[22]  R. W. Hornbeck,et al.  Laminar flow in the entrance region of a pipe , 1964 .

[23]  R Hendrickson,et al.  Phenotype dictates the growth response of vascular smooth muscle cells to pulse pressure in vitro. , 1999, Experimental cell research.

[24]  M. Nugent,et al.  Potential mechanisms for the regulation of growth factor binding by heparin. , 2000, Journal of theoretical biology.

[25]  Aleksander S. Popel,et al.  A Reaction-Diffusion Model of Basic Fibroblast Growth Factor Interactions with Cell Surface Receptors , 2004, Annals of Biomedical Engineering.

[26]  Jun Zhang,et al.  A Numerical Study of Pulsatile Flow Through a Hollow Fiber Cartridge: Growth Factor-Receptor Binding and Dissociation Analysis , 2009, 2009 International Joint Conference on Bioinformatics, Systems Biology and Intelligent Computing.

[27]  B. Olwin,et al.  Requirement of heparan sulfate for bFGF-mediated fibroblast growth and myoblast differentiation , 1991, Science.

[28]  D. Moscatelli,et al.  High and low affinity binding sites for basic fibroblast growth factor on cultured cells: Absence of a role for low affinity binding in the stimulation of plasminogen activator production by bovine capillary endothelial cells , 1987, Journal of cellular physiology.

[29]  James H. Brown,et al.  The fourth dimension of life: fractal geometry and allometric scaling of organisms. , 1999, Science.

[30]  Shijie Sheng,et al.  Prostate cancer cell-derived urokinase-type plasminogen activator contributes to intraosseous tumor growth and bone turnover. , 2008, Neoplasia.

[31]  Jeffrey D. Esko,et al.  Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor , 1991, Cell.

[32]  M. Nugent,et al.  Basic Fibroblast Growth Factor Binds Its Receptors, Is Internalized, and Stimulates DNA Synthesis in Balb/c3T3 Cells in the Absence of Heparan Sulfate* , 1996, The Journal of Biological Chemistry.

[33]  Aleksander S Popel,et al.  Intracoronary administration of FGF-2: a computational model of myocardial deposition and retention. , 2005, American Journal of Physiology. Heart and Circulatory Physiology.

[34]  G. Sledge,et al.  Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  J. J. Schwartz,et al.  Heparan sulfate proteoglycans of the cardiovascular system. Specific structures emerge but how is synthesis regulated? , 1997, The Journal of clinical investigation.

[36]  Kimberly Forsten-Williams,et al.  Control of Growth Factor Networks by Heparan Sulfate Proteoglycans , 2008, Annals of Biomedical Engineering.

[37]  J. Xu,et al.  An essential heparin-binding domain in the fibroblast growth factor receptor kinase. , 1993, Science.

[38]  M. Nugent,et al.  Mechanisms of fibroblast growth factor 2 intracellular processing: a kinetic analysis of the role of heparan sulfate proteoglycans. , 2000, Biochemistry.

[39]  M. Nugent,et al.  Endothelial proteoglycans inhibit bFGF binding and mitogenesis , 1997, Journal of cellular physiology.

[40]  D. Moscatelli,et al.  Basic fibroblast growth factor (bFGF) dissociates rapidly from heparan sulfates but slowly from receptors. Implications for mechanisms of bFGF release from pericellular matrix. , 1992, The Journal of biological chemistry.

[41]  J. Winer,et al.  The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. , 1992, Growth factors.

[42]  A. Popel,et al.  Dimerization of VEGF receptors and implications for signal transduction: a computational study. , 2007, Biophysical chemistry.

[43]  P. Cahill,et al.  Flow-mediated regulation of endothelin receptors in cocultured vascular smooth muscle cells: an endothelium-dependent effect. , 1997, Journal of vascular research.

[44]  J. Folkman,et al.  Angiogenic factors. , 1987, Science.

[45]  Robert E. Wilson,et al.  Fundamentals of momentum, heat, and mass transfer , 1969 .

[46]  J. Schlessinger,et al.  Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. , 2000, Molecular cell.

[47]  Kimberly Forsten-Williams,et al.  The kinetics of FGF-2 binding to heparan sulfate proteoglycans and MAP kinase signaling. , 2005, Journal of theoretical biology.

[48]  Kimberly Forsten-Williams,et al.  Binding inhibition of angiogenic factors by heparan sulfate proteoglycans in aqueous humor: potential mechanism for maintenance of an avascular environment , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.